Cover Image

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Show other versions (1)

Purpose Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK1 receptor antagonist (RA), netupitant (NETU 300mg), and palonosetron (PALO 0.50 mg), a pharmacologically disti...

Full description

Bibliographic Details
Main Authors: Aapro, Matti, Karthaus, Meinolf, Schwartzberg, Lee, Bondarenko, Igor, Sarosiek, Tomasz, Oprean, Cristina, Cardona Huerta, Servando, Hansen, Vincent, Rossi, Giorgia, Rizzi, Giada, Borroni, Maria Elisa, Rugo, Hope
Format: Article
Language:English
Published: 2017
Subjects:
RC Medicina Interna, Psiquiatría, Neurología
Online Access:http://eprints.uanl.mx/14551/1/63.pdf

Similar Items

Similar Items